Understanding the DEA and BCBSM Investigation Dynamics

An illustration titled 'Unmasking the Pharmacy Benefit Manager' showing a figure representing the healthcare middleman with arrows directing towards healthcare and employer/plan sponsor icons, highlighting the hidden costs in healthcare plans. — The Pharmacy Benefit Manager (PBM) has strategically entrenched itself as a self-appointed gatekeeper, operating within the critical friction points between health insurance plan sponsors, patients, and pharmacists.

Why PBMs profit from expensive drugs

youarewithinthenorms.com

NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, IN THE SPIRIT OF WALTER R. CLEMENT MS., MBA., BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., IN THE SPIRIT OF REV. C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF WILLIE GUINYARD BS., IN THE SPIRIT OF ERLIN CLEMENT SR., JOSEPH WEBSTER MD., MBA, IN THE SPIRIT OF RICHARD KAUL, MD., BEVERLY C. PRINCE MD., FACS., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, IN THE SPIRIT OF WALTER F. WRENN III, MD., ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NDJOU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

Contact information and quote from Steven R. Ariens, a chronic pain patient advocate and pharmacist, along with a cartoon illustration of a pharmacist. — FROM PHARMACIST STEVE

Graphic comparing the promise of cost reduction in healthcare with the reality of profit extraction, featuring points on benefits management, prescription negotiations, and financial implications.

A table with two books titled 'DOCTOR NOT GUILTY' and 'USA RAJ' displayed on it, with a scenic view of blue skies and water in the background. The phrase 'IF YOU DON’T FIGHT, YOU CAN'T WIN' is visible at the top. — FROM **youarewithinthenorms**: “IF YOU DON’T FIGHT, YOU CAN’T WIN”

PBMs’, THE MIDDLEMAN CUTS OPERATING IN THE SHADOWS OF YOUR HEALTH PLAN

By restricting patient choice through mandated mail-order services they own, PBMs are depicted as prioritising their own corporate profits over the well-being of consumers. Ultimately, the source serves as a critique of the industry’s lack of transparency , urging employers and patients to demand reform to lower prescription costs.

Text graphic stating 'THE GOAL OF THE SWARM: POWER. PROFIT. CONTROL.' on a black background. — **Dr. Shiva Ayyadurai, SWARM** ETC. PBM

The Intermediary Positioning: Analyzing the PBM’s Role in Healthcare Ecosystems

The Pharmacy Benefit Manager (PBM) has strategically entrenched itself as a self-appointed gatekeeper, operating within the critical friction points between health insurance plan sponsors, patients, and pharmacists. Originally conceived to provide Administrative Services Only (ASO) to streamline claims, these entities have transitioned into aggressive middlemen.

Infographic explaining 'Tactic 1: The Script Scam and hidden markups' in healthcare, illustrating the flow of pricing from Insurance Plans to Pharmacy Benefit Managers (PBM) and Dispensing Pharmacies, highlighting hidden costs labeled 'The Spread'. — By obstructing the direct relationship between the payer and the provider, the PBM creates a controlled environment where value is diverted away from the plan and into the PBM’s proprietary accounts.

For the health plan sponsor, recognizing this intermediary positioning is the first step in identifying systemic financial leakages. By obstructing the direct relationship between the payer and the provider, the PBM creates a controlled environment where value is diverted away from the plan and into the PBM’s proprietary accounts.

This video uses a satirical character named “Phil My Pockets” to illustrate the controversial role of Pharmacy Benefit Managers (PBMs) as hidden intermediaries in the healthcare system. The narrative reveals how these entities often manipulate drug pricing by marking up costs and accepting payments from pharmaceutical companies to prioritize specific medications.

Infographic illustrating tactics used by Pharmacy Benefit Managers (PBMs) to negotiate with large pharmaceutical companies, highlighting direct payments, kickbacks, and the impact on drug pricing. — The current power dynamic allows the PBM to “call the shots” regarding medication access, fundamentally dictating the “when, where, and how” of prescription fulfillment.

The current power dynamic allows the PBM to “call the shots” regarding medication access, fundamentally dictating the “when, where, and how” of prescription fulfillment.

A concerned elderly woman with gray hair looks at a young Black male doctor wearing a white coat and stethoscope, expressing a serious conversation in a medical setting. — THE COLLATERAL DAMAGE OF THE MIDDLEMAN MONOPOLY

This absolute control over pharmacy network adequacy and formulary access subverts the sponsor’s primary objective of sustainable cost reduction. Rather than serving as a neutral administrator, the PBM leverages its gatekeeper status to prioritize internal profit margins over the plan’s fiscal integrity or beneficiaries’ clinical outcomes.

The PBM’s interference manifests as a direct conflict of interest across three primary stakeholder groups:

Sponsors (Employers): PBMs manipulate the benefit design to maximize their own revenue, often failing to deliver promised savings while charging the sponsor a significant premium over the actual cost of the drug.
Patients: Through restricted formularies and mandated provider channels, PBMs strip patients of autonomy, limiting access to essential medications based on the PBM’s financial incentives.
Pharmacists: Independent pharmacists are systematically “cut out” or marginalized as PBMs utilize their market power to redirect volume toward PBM-owned entities, eroding local pharmacy network stability.

Beyond these structural barriers, we must examine the specific accounting maneuvers—most notably non-transparent spread revenue—used to divert plan assets into PBM coffers.

Diagram explaining forced pharmacy steering and removal of patient choice, depicting a patient directed towards a mail-order pharmacy owned by a Pharmacy Benefit Manager (PBM) instead of a neighborhood pharmacist.

The Mechanics of Spread Pricing: Deconstructing the “Script Scam”

There has been a calculated strategic shift in the PBM business model, moving away from transparent fee-for-service arrangements toward a “Principal-based” profit model. In this evolution, PBMs have largely abandoned their role as simple paperwork processors in favor of opaque pricing structures designed to generate arbitrage opportunities.

The cornerstone of this model is what the industry colloquially refers to as the “script scam,” or spread pricing.

Diagram illustrating the interrelation between BCBSM investigations and federal probes, featuring two interlocking gears and highlighting key arguments and evidence related to the investigation. — This-Mechanicanized Partnership-conspiracy-between-DEA-and-Blue-Cross-Blue-Shield. PERRY vs. DEA and Pompy vs Blue Cross Blue Shield Michigan, D.E.A, et al

In this maneuver, the PBM charges the insurance plan a high premium for a medication while simultaneously reimbursing the dispensing pharmacy at a significantly lower rate. The PBM then retains the difference—the “spread”—as undisclosed revenue. This “shady scheme” ensures that the PBM profits from every transaction, effectively marking up medications and pocketing the delta without the sponsor’s knowledge or consent.

PBM Stated Value Proposition	Actual Fiscal Outcome (Auditor Analysis)
Cost Containment: Negotiating lower drug prices for the plan.	Reimbursement Spread Retention: Retaining the undisclosed invoice-to-claim delta as internal profit.
Administrative Support: Providing back-end processing for claims.	Principal-Based Arbitrage: Utilizing the “script scam” to facilitate hidden markups on essential medications.

These hidden markups significantly distort pharmaceutical market transparency, as the true cost of the drug is obscured by the PBM’s desire to accumulate internal capital.

A focused elderly male doctor in a white coat examines a medical chart or device in a dimly lit hospital room, while two other medical professionals attend to a patient in the background. — THE COLLATERAL DAMAGE OF THE MIDDLEMAN MONOPOLY

Manufacturer Rebates and the Distortion of Formulary Selection

A medical professional holding a judicial gavel in a pharmacy setting, surrounded by shelves of medications. — NCPA:”WAR ONTO PBM MIDDLEMAN SCAM”

THE NCPA DECLARES WAR ON PBM MIDDLEMAN SCFIPT SCAM PROCEDURES

The strategic implications of PBMs negotiating directly with “Big Brand” pharmaceutical manufacturers are profound, often resulting in a direct violation of fiduciary misalignment. These negotiations are not aimed at clinical efficacy but at securing “sweet deals” where manufacturers pay the PBM to grant “favored” status to high-cost medications over more affordable, clinically equivalent alternatives.

This “pay-to-play” system incentivizes PBMs to build formularies based on rebate aggregation potential rather than the sponsor’s cost-effectiveness goals.

A serious businessman in a suit stands confidently in an office environment, with dollar bills falling around him. — Dr. Shiva Ayyadurai, SWARM PBM

When a PBM prioritizes a brand-name drug because it offers a higher back-end payment, the plan sponsor is forced to pay higher upfront costs, while the PBM secures the rebate as “other revenue.”

The consequences of these manufacturer-PBM deals include:

Erosion of Clinical Neutrality: Patient drug choices are restricted to medications that maximize PBM profit rather than patient health.
Inflated Plan Costs: The preference for high-cost “rebate-heavy” drugs artificially inflates the sponsor’s total spend and drives up insurance premiums.
Formulary Exclusion Risks: Low-cost generics are often excluded or placed on high-cost tiers to protect the PBM’s “sweet deals” with brand manufacturers.

These financial incentives naturally drive the push toward PBM-owned service channels, where the PBM can capture both the spread and the rebate in a closed-loop system.

A 3D illustration depicting a pharmacy-themed community with buildings labeled 'Pharmacy' and 'PBM,' featuring a dollar sign and various pharmaceutical products.

Vertical Integration: The Fiscal Impact of Mandated Mail-Order Services

PBMs have aggressively pursued vertical integration, owning the pharmacies they are supposedly managing objectively. This creates a monopolistic feedback loop that eliminates competition from independent neighborhood pharmacies. By mandating the use of PBM-owned mail-order services, these intermediaries ensure they capture every dollar of the transaction—from the administrative fee to the pharmacy’s professional margin.

A laboratory technician in a white lab coat, wearing gloves, a face mask, and protective eyewear, analyzes contents in glass bottles on a countertop, surrounded by shelves of various chemicals, illuminated by pink and blue lights.

The removal of the “neighborhood pharmacist” from the care continuum through forced mail-order creates several critical risks:

Service Level Degradation (“Lousy Service”): Patients are forced away from personalized local care and into centralized, automated systems that frequently suffer from delivery delays and poor customer support.
Anti-Competitive Choice Restriction: The PBM “calls the shots” by stripping the patient of pharmacy choice, forcing them into a proprietary channel that the PBM manages for its own benefit.
Aggressive Capital Extraction (“Huge Piles of Cash”): By owning the mail-order channel, the PBM can rake in massive profits without the pricing pressure of a competitive retail network.

An illustrated pharmacy interior featuring shelves stocked with various medications, a checkout area, and signage indicating it is a PBM-owned pharmacy. Arrows provide information on services and pharmacy operations.

Plan sponsors are often left with zero visibility into these integrated operations, as PBMs use their ownership status to shield their internal margins from audit or scrutiny.

Two men in business suits standing by a glass revolving door, with backlighting creating silhouettes.

Transparency and the “Shadow” Economy of Pharmacy Benefits

Transparency is the bedrock of fiduciary management, yet PBMs strategically “prefer to work in the shadows.” This lack of visibility is the core component of a business model built on information asymmetry. By keeping sponsors, pharmacists, and patients “in the dark,” PBMs protect their ability to execute “shady schemes” that would not survive the light of a rigorous audit.

Close-up of a 'Risk Summary' document with a pen and a stethoscope, surrounded by various financial charts and a geometric orange shape.

Risk Summary and Fiduciary Warning: Health plan sponsors face extreme fiscal and legal risk by failing to audit their PBMs’ profit-taking methods. Under ERISA guidelines, sponsors have a fiduciary duty to manage plan assets solely for the benefit of participants. Allowing a PBM to “rake in profits” through non-transparent spread pricing and rebate retention while remaining “in the dark” may constitute a breach of that fiduciary duty.

A group of five professionals in business attire engaged in a meeting around a glass table, reviewing documents and charts in a modern office setting.

The current PBM model relies on stakeholders remaining unaware of the financial mechanisms at play. For plan sponsors seeking to reclaim control, protect patient choice, and restore fiscal integrity, the first step is a comprehensive audit of all PBM contracts and a transition to transparent, pass-through models.

A shadowy figure walking through a modern aisle illuminated by vibrant pink and blue neon lights, with shelves lined with various products.

For more information on reforming these practices and identifying who is truly managing your pharmacy spend, visit who runs your drug plan. The era of the “shadow” middleman must end to ensure the long-term viability of the healthcare ecosystem.